APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Prevention and Treatment Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis Prevention and Treatment Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchTuberculosis Prevention and Treatment Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Prevention and Treatment Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Tuberculosis Prevention and Treatment Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Prevention and Treatment Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Prevention and Treatment Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Tuberculosis Prevention and Treatment Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tuberculosis Prevention and Treatment Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Prevention and Treatment Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Prevention and Treatment Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tuberculosis Prevention and Treatment Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tuberculosis Prevention and Treatment Vaccine market include Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC, GreenSignal Bio Pharma and China National Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Prevention and Treatment Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Prevention and Treatment Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Prevention and Treatment Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Prevention and Treatment Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Prevention and Treatment Vaccine Segment by Company

Merck

Taj Pharmaceuticals

Serum Institute of India

Queen Saovabha Mem. Inst

Microgen

Japan BCG Lab

IVAC

GreenSignal Bio Pharma

China National Biotec

Biomed Lublin

BioFarma

Ataulpho de Paiva

AJ Vaccines

Tuberculosis Prevention and Treatment Vaccine Segment by Type

Immune Vaccine

Therapy Vaccine

Tuberculosis Prevention and Treatment Vaccine Segment by Application

Self-Procurement

UNICEF

Other

Tuberculosis Prevention and Treatment Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tuberculosis Prevention and Treatment Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tuberculosis Prevention and Treatment Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis Prevention and Treatment Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis Prevention and Treatment Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Prevention and Treatment Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Prevention and Treatment Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Prevention and Treatment Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Prevention and Treatment Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Prevention and Treatment Vaccine industry.

Chapter 3: Detailed analysis of Tuberculosis Prevention and Treatment Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tuberculosis Prevention and Treatment Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tuberculosis Prevention and Treatment Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Prevention and Treatment Vaccine Industry Trends Table 2. Tuberculosis Prevention and Treatment Vaccine Industry Drivers Table 3. Tuberculosis Prevention and Treatment Vaccine Industry Opportunities and Challenges Table 4. Tuberculosis Prevention and Treatment Vaccine Industry Restraints Table 5. Global Tuberculosis Prevention and Treatment Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Prevention and Treatment Vaccine Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Tuberculosis Prevention and Treatment Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Tuberculosis Prevention and Treatment Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tuberculosis Prevention and Treatment Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Tuberculosis Prevention and Treatment Vaccine Company, Product Type & Application Table 13. Global Tuberculosis Prevention and Treatment Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Prevention and Treatment Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immune Vaccine Table 18. Significant Companies of Therapy Vaccine Table 19. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Self-Procurement Table 30. Significant Companies of UNICEF Table 31. Significant Companies of Other Table 32. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Tuberculosis Prevention and Treatment Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Tuberculosis Prevention and Treatment Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Tuberculosis Prevention and Treatment Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Tuberculosis Prevention and Treatment Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Tuberculosis Prevention and Treatment Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Tuberculosis Prevention and Treatment Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Tuberculosis Prevention and Treatment Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Tuberculosis Prevention and Treatment Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Tuberculosis Prevention and Treatment Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Global Tuberculosis Prevention and Treatment Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Tuberculosis Prevention and Treatment Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Tuberculosis Prevention and Treatment Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Merck Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 68. Merck Recent Development Table 69. Taj Pharmaceuticals Company Information Table 70. Taj Pharmaceuticals Business Overview Table 71. Taj Pharmaceuticals Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Taj Pharmaceuticals Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 73. Taj Pharmaceuticals Recent Development Table 74. Serum Institute of India Company Information Table 75. Serum Institute of India Business Overview Table 76. Serum Institute of India Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Serum Institute of India Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 78. Serum Institute of India Recent Development Table 79. Queen Saovabha Mem. Inst Company Information Table 80. Queen Saovabha Mem. Inst Business Overview Table 81. Queen Saovabha Mem. Inst Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Queen Saovabha Mem. Inst Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 83. Queen Saovabha Mem. Inst Recent Development Table 84. Microgen Company Information Table 85. Microgen Business Overview Table 86. Microgen Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Microgen Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 88. Microgen Recent Development Table 89. Japan BCG Lab Company Information Table 90. Japan BCG Lab Business Overview Table 91. Japan BCG Lab Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Japan BCG Lab Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 93. Japan BCG Lab Recent Development Table 94. IVAC Company Information Table 95. IVAC Business Overview Table 96. IVAC Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. IVAC Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 98. IVAC Recent Development Table 99. GreenSignal Bio Pharma Company Information Table 100. GreenSignal Bio Pharma Business Overview Table 101. GreenSignal Bio Pharma Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. GreenSignal Bio Pharma Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 103. GreenSignal Bio Pharma Recent Development Table 104. China National Biotec Company Information Table 105. China National Biotec Business Overview Table 106. China National Biotec Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. China National Biotec Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 108. China National Biotec Recent Development Table 109. Biomed Lublin Company Information Table 110. Biomed Lublin Business Overview Table 111. Biomed Lublin Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Biomed Lublin Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 113. Biomed Lublin Recent Development Table 114. BioFarma Company Information Table 115. BioFarma Business Overview Table 116. BioFarma Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. BioFarma Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 118. BioFarma Recent Development Table 119. Ataulpho de Paiva Company Information Table 120. Ataulpho de Paiva Business Overview Table 121. Ataulpho de Paiva Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Ataulpho de Paiva Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 123. Ataulpho de Paiva Recent Development Table 124. AJ Vaccines Company Information Table 125. AJ Vaccines Business Overview Table 126. AJ Vaccines Tuberculosis Prevention and Treatment Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. AJ Vaccines Tuberculosis Prevention and Treatment Vaccine Product Portfolio Table 128. AJ Vaccines Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Tuberculosis Prevention and Treatment Vaccine Distributors List Table 132. Tuberculosis Prevention and Treatment Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Tuberculosis Prevention and Treatment Vaccine Product Image Figure 2. Global Tuberculosis Prevention and Treatment Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Prevention and Treatment Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Tuberculosis Prevention and Treatment Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Tuberculosis Prevention and Treatment Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immune Vaccine Image Figure 10. Therapy Vaccine Image Figure 11. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type (2021-2032) Figure 17. Self-Procurement Image Figure 18. UNICEF Image Figure 19. Other Image Figure 20. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Tuberculosis Prevention and Treatment Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Tuberculosis Prevention and Treatment Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Tuberculosis Prevention and Treatment Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Tuberculosis Prevention and Treatment Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Vaccine
  • Therapy Vaccine
Applications
  • Self-Procurement
  • UNICEF
  • Other
Companies covered
  • Merck
  • Taj Pharmaceuticals
  • Serum Institute of India
  • Queen Saovabha Mem. Inst
  • Microgen
  • Japan BCG Lab
  • IVAC
  • GreenSignal Bio Pharma
  • China National Biotec
  • Biomed Lublin
  • BioFarma
  • Ataulpho de Paiva
  • AJ Vaccines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tuberculosis Prevention and Treatment Vaccine Market Dynamics
  1. 2.1 Tuberculosis Prevention and Treatment Vaccine Industry Trends
  2. 2.2 Tuberculosis Prevention and Treatment Vaccine Industry Drivers
  3. 2.3 Tuberculosis Prevention and Treatment Vaccine Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Prevention and Treatment Vaccine Industry Restraints
3 Tuberculosis Prevention and Treatment Vaccine Market by Company
  1. 3.1 Global Tuberculosis Prevention and Treatment Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis Prevention and Treatment Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Tuberculosis Prevention and Treatment Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Tuberculosis Prevention and Treatment Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Tuberculosis Prevention and Treatment Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Tuberculosis Prevention and Treatment Vaccine Company Product Type and Application
  8. 3.8 Global Tuberculosis Prevention and Treatment Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tuberculosis Prevention and Treatment Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tuberculosis Prevention and Treatment Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Prevention and Treatment Vaccine Market by Type
  1. 4.1 Tuberculosis Prevention and Treatment Vaccine Type Introduction
  2. 4.1.1 Immune Vaccine
  3. 4.1.2 Therapy Vaccine
  4. 4.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type
  5. 4.2.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type
  9. 4.3.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type (2021-2032)
5 Tuberculosis Prevention and Treatment Vaccine Market by Application
  1. 5.1 Tuberculosis Prevention and Treatment Vaccine Application Introduction
  2. 5.1.1 Self-Procurement
  3. 5.1.2 UNICEF
  4. 5.1.3 Other
  5. 5.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application
  6. 5.2.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application
  10. 5.3.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application (2021-2032)
6 Tuberculosis Prevention and Treatment Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Tuberculosis Prevention and Treatment Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Prevention and Treatment Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Prevention and Treatment Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis Prevention and Treatment Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Tuberculosis Prevention and Treatment Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tuberculosis Prevention and Treatment Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis Prevention and Treatment Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Tuberculosis Prevention and Treatment Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tuberculosis Prevention and Treatment Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Tuberculosis Prevention and Treatment Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Tuberculosis Prevention and Treatment Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tuberculosis Prevention and Treatment Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tuberculosis Prevention and Treatment Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Taj Pharmaceuticals
  8. 8.2.1 Taj Pharmaceuticals Company Information
  9. 8.2.2 Taj Pharmaceuticals Business Overview
  10. 8.2.3 Taj Pharmaceuticals Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Taj Pharmaceuticals Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  12. 8.2.5 Taj Pharmaceuticals Recent Developments
  13. 8.3 Serum Institute of India
  14. 8.3.1 Serum Institute of India Company Information
  15. 8.3.2 Serum Institute of India Business Overview
  16. 8.3.3 Serum Institute of India Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute of India Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  18. 8.3.5 Serum Institute of India Recent Developments
  19. 8.4 Queen Saovabha Mem. Inst
  20. 8.4.1 Queen Saovabha Mem. Inst Company Information
  21. 8.4.2 Queen Saovabha Mem. Inst Business Overview
  22. 8.4.3 Queen Saovabha Mem. Inst Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Queen Saovabha Mem. Inst Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  24. 8.4.5 Queen Saovabha Mem. Inst Recent Developments
  25. 8.5 Microgen
  26. 8.5.1 Microgen Company Information
  27. 8.5.2 Microgen Business Overview
  28. 8.5.3 Microgen Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Microgen Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  30. 8.5.5 Microgen Recent Developments
  31. 8.6 Japan BCG Lab
  32. 8.6.1 Japan BCG Lab Company Information
  33. 8.6.2 Japan BCG Lab Business Overview
  34. 8.6.3 Japan BCG Lab Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Japan BCG Lab Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  36. 8.6.5 Japan BCG Lab Recent Developments
  37. 8.7 IVAC
  38. 8.7.1 IVAC Company Information
  39. 8.7.2 IVAC Business Overview
  40. 8.7.3 IVAC Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 IVAC Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  42. 8.7.5 IVAC Recent Developments
  43. 8.8 GreenSignal Bio Pharma
  44. 8.8.1 GreenSignal Bio Pharma Company Information
  45. 8.8.2 GreenSignal Bio Pharma Business Overview
  46. 8.8.3 GreenSignal Bio Pharma Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GreenSignal Bio Pharma Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  48. 8.8.5 GreenSignal Bio Pharma Recent Developments
  49. 8.9 China National Biotec
  50. 8.9.1 China National Biotec Company Information
  51. 8.9.2 China National Biotec Business Overview
  52. 8.9.3 China National Biotec Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 China National Biotec Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  54. 8.9.5 China National Biotec Recent Developments
  55. 8.10 Biomed Lublin
  56. 8.10.1 Biomed Lublin Company Information
  57. 8.10.2 Biomed Lublin Business Overview
  58. 8.10.3 Biomed Lublin Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biomed Lublin Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  60. 8.10.5 Biomed Lublin Recent Developments
  61. 8.11 BioFarma
  62. 8.11.1 BioFarma Company Information
  63. 8.11.2 BioFarma Business Overview
  64. 8.11.3 BioFarma Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 BioFarma Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  66. 8.11.5 BioFarma Recent Developments
  67. 8.12 Ataulpho de Paiva
  68. 8.12.1 Ataulpho de Paiva Company Information
  69. 8.12.2 Ataulpho de Paiva Business Overview
  70. 8.12.3 Ataulpho de Paiva Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Ataulpho de Paiva Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  72. 8.12.5 Ataulpho de Paiva Recent Developments
  73. 8.13 AJ Vaccines
  74. 8.13.1 AJ Vaccines Company Information
  75. 8.13.2 AJ Vaccines Business Overview
  76. 8.13.3 AJ Vaccines Tuberculosis Prevention and Treatment Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AJ Vaccines Tuberculosis Prevention and Treatment Vaccine Product Portfolio
  78. 8.13.5 AJ Vaccines Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Prevention and Treatment Vaccine Value Chain Analysis
  2. 9.1.1 Tuberculosis Prevention and Treatment Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Prevention and Treatment Vaccine Sales Mode & Process
  6. 9.2 Tuberculosis Prevention and Treatment Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Prevention and Treatment Vaccine Distributors
  9. 9.2.3 Tuberculosis Prevention and Treatment Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst